3646 results for «747»
3646 results
Hybrid procedure: Stent and DCB for a long diffuse lesion - LIVE case
05 Oct 2024 – From AICT-AsiaPCR 2024
A 40-year-old male with no comorbidities presented an NSTEMI. The angiography showed a focus lesion on the mid-CX and a diffuse lesion on the mid and distal LAD. The LAD FFR are 0.49 with a diffuse pullback gradient.
After Stent in mid-CX guided by OCT, the operators...
Complications in women: crash and burn or crash and save
05 Oct 2024 – From AICT-AsiaPCR 2024
Complications can arise even in the most experienced hands. This session explores a series of challenging cases involving women, from a detached mitral clip to a calcified vessel perforation. Witness the crash and burn moments, but also the heroic crash and save interventions, as our experts...
Complex STEMI cases: Dextrocardia, thrombosis and coronary aneurysms
05 Oct 2024 – From AICT-AsiaPCR 2024
Prepare to be captivated by a collection of intriguing STEMI cases, curated from the AICT-AsiaPCR 2024 submissions. From a left main PCI in a patient with dextrocardia to a challenging case of primary PCI in an aneurysmal coronary artery, this session promises to push the boundaries...
How should I treat complex lesion from the intracoronary imaging view?
05 Oct 2024 – From AICT-AsiaPCR 2024
Intracoronary imaging plays a crucial role in guiding treatment strategies for complex lesions. This session delves into the use of various imaging modalities, such as IVUS and OCT, to optimize PCI outcomes. Explore real-world case examples, including a sudden coronary arrest caused by focal stenosis with...
Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial
31 Oct 2025
Nicola Ryan provides her take on the PROMISE trial presented by Rocco Antonio Montone at TCT 2025, in San Francisco.

Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author